泛昔洛韦联合干扰素治疗慢性乙型肝炎的研究

Study of famciclovir combined with interferon-α on chronic hepatitis B

目的 评价泛昔洛韦联合α- 1b干扰素治疗慢性乙型肝炎的疗效和安全性。方法 将77例慢性乙型肝炎患者随机分为治疗组和对照组 ,均予一般护肝药物和α - 1b干扰素治疗 ,治疗组加服泛昔洛韦。观察患者血清ALT的变化、HBV -DNA和HBeAg阴转率以及用药后的不良反应。结果 治疗组HBV -DNA ,HBeAg阴转率明显高于对照组 (P <0 .0 1)。治疗组患者除有短期轻度头痛外 ,与对照组相比未见其他不良反应。

Objective It is to explore the efficacy and safety of famciclovir combined with interferon-α on chronic hepatitis B. Methods Seventy seven patients with chronic hepatitis B were randomly divided into treatment group (41 cases) and control group (36 cases). Based on general treatment, the treatment group were given famciclovir combined with interferon-α, while the control group (36 cases) were given interferon-α. After treatment serum ALT, the seroconversion rate of HBV-DNA and HBeAg in two groups were detected respectively and untoward reaction were observed. Results The seroconversion rate of HBV-DNA, HBeAg in the treatment group were higher than those in the control group ( P <0.01). Compared with the control group, no untoward reaction was found in the treatment except for short term slight headache. Conclusion famciclovir combined with interferon-αis effective and safety on chronic hepatitis B.